Showing results 1 – 6 of 6

Philip McCarthy

Director of the Blood and Marrow Transplant Center

Roswell Park Comprehensive Cancer Center

Bone Marrow, Bone Marrow Transplant, Leukemia, Lymphoma, Multiple Myeloma, Cancer, Blood Cancer, hematologic oncology

Director of the Blood and Marrow Transplant Center, Roswell Park Cancer Institute
Areas of expertise: Bone marrow transplant, leukemia, lymphoma, multiple myeloma, blood cancer, hematologic oncology

Marco Mielcarek

Medical Director of the Adult Blood and Marrow Tra

Seattle Cancer Care Alliance

Cancer, Bone Marrow, Oncology, Blood Cancers, Stem Cell, Transplantation

Sickle Cell Disease, Hemophilia, Blood Cancer, Blood Disease

Modupe Idowu, MD, treats patients with sickle cell anemia, myeloproliferative neoplasm, thrombotic disorders, and hematologic malignancy including lymphoproliferative disorders, plasma cell dyscracias, and leukemias. Her research interests in clinical and translational investigations involve sickle cell anemia and thrombotic disorders. She is the medical director of the UT Physicians Comprehensive Sickle Cell Center.

Mohamad Cherry MD

Medical Director, Hematology, Atlantic Health System Cancer Care

Atlantic Health System

Hematology, Medical Oncology, Clinical Trials, hematologic malignancies, new therapeutics for relapsed and refractory blood cancers, Epigenetics

Triple board-certified in internal medicine, hematology and medical oncology, Dr. Mohamad Cherry is medical director of Hematology at Atlantic Health System Cancer Care. He joined Atlantic Hematology Oncology from the University of Oklahoma Health Sciences Center's Stephenson Cancer Center, bringing years of clinical knowledge and expertise.

With specialty training from some of the nation's most skilled clinicians, Dr. Cherry attained some of his clinical training at the leukemia department at MD Anderson and his fellowship in hematology/oncology from the University of Oklahoma Health Sciences Center's Stephenson Cancer Center. He performed two residencies - an internal medicine residency at Staten Island University Hospital and a laboratory medicine residency at the American University of Beirut Medical Center in Lebanon. Previously, Dr. Cherry attained his medical degree at Lebanese University and performed his internship at Sacre Coeur Hospital-Lebanese University. He also earned a master of science degree in clinical and translational research from University of Oklahoma College of Public Health.

Dr. Cherry remains on staff as clinical associate professor of hematology/oncology at University of Oklahoma Health Sciences Center's Stephenson Cancer Center. He is also the director of its hematology/oncology fellowship program and co-chairs the Academy of Teaching Scholars Faculty Development, Education and Mentoring Committee. Other administrative roles include co-chair of the leukemia working group at the Sarah Cannon Research Institute Blood Cancer Consortium.

As a principal investigator of multiple clinical trials, Dr. Cherry has performed groundbreaking research in niche areas that include epigenetics and development of new therapeutics in relapsed and refractory blood cancers. He has developed teaching materials and book chapters, and has lectured both nationally and internationally.

Dr. Cherry continues to serves as a mentor and an advisor to fellows, residents and medical students. He contributes to continuing education, public health, and professional development, and has won awards and funding for both his research and his clinical pursuits.

David Maloney

Medical Director, Cellular Immunotherapy Integrated Research Center at Fred Hutch

Fred Hutchinson Cancer Research Center

CAR T-cell therapy, Immunotherapy, Chimeric antigen receptor T-cell, Lymphoma, Leukemia, Myeloma, cancer immunotherapies, Blood Cancers, ofatumumab, Arzerra, Hematopoietic

Physician-scientist Dr. David Maloney is at the forefront of clinical trials to develop cell therapies for blood and other cancers, including understanding side effects of CAR T’s and how to deliver them in outpatient settings. A renowned researcher and clinician focusing on cancer immunotherapies and CAR T-cell therapies, he recently presented findings from the TRANSCEND trial for CD19 CAR T. This study showed that patients had improved quality-of-life (reduced fatigue and pain symptoms) starting six months after receiving CAR T-cell therapy. 

Dr. Maloney focuses on using genetically engineered T cells (such as CAR-T) to treat patients with leukemia, lymphoma, myeloma and selected other cancers without causing graft vs. host disease that has been associated with transplantation.  He was instrumental in developing and testing rituximab, the first antibody-based cancer drug on the market – one that has transformed the treatment of certain leukemias and lymphomas.

He is also an expert on blood-forming (hematopoietic) stem cell transplantation (HCT) in using a matched donor’s (allogeneic) or a patient’s own (autologous) stem cells in treatments for patients with hematologic malignancies. Recognizing that standard pre-transplant regimens are too toxic for many patients, Dr. Maloney and Fred Hutch colleagues are evaluating approaches that use antibodies to deliver radioactivity or cancer-killing drugs directly to tumors. They have also developed a less toxic, “reduced intensity” (nonmyeloablative) regimen that can more safely provide long-term remissions for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin Lymphoma (NHL) and myeloma after allogeneic HCT.

Autologous HCT followed by reduced intensity allogenic HCT (tandem HCT) has proven effective for refractory NHL and myeloma patients. Dr. Maloney and colleagues have learned that nearly all of the anti-tumor activity of allogeneic HCT comes from the specific graft-vs-tumor activities of donor immune T cells, showing that antitumor immunity can be curative. Unfortunately, these T cells can also cause dangerous “graft-vs-host” effects on normal tissues.

Dr. Maloney continues exploring the use of antibodies as anti-cancer therapies, including newer anti-CD20 antibodies (e.g. ofatumumab, Arzerra®) for NHL patients, as well as radiolabeled antibodies, drug-carrying antibodies and unlabeled antibodies as targeted pre-transplant “conditioning” or as “maintenance” to extend remissions after allogeneic transplantation.

As medical director of the Cellular Immunotherapy Integrated Research Center at Fred Hutch, Dr. Maloney cares for patients at the Bezos Family Immunotherapy Clinic at Seattle Cancer Care Alliance, the Hutch’s clinical-care partner. He is also professor of medicine in the Division of Oncology at the University of Washington.

Oncologist, Lymphoma (Hodgkin lymphoma and non-Hodgkin lymphoma), Blood Disorders, Blood Cancer, Leukemia, Hematology

Dr. Andrew M. Evens is a physician-scientist at the Rutgers Cancer Institute of New Jersey, where he is Associate Director for Clinical Services and Director of the Lymphoma Program. In addition, he is the Medical Director of the Oncology Service Line for the RWJBarnabas Health system. Dr. Evens completed a Hematology/Oncology fellowship at Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center, where he was also Director of Translational Therapeutics. Prior to his Rutgers Cancer Institute appointment, Dr. Evens served as Chief of the Division of Hematology/Oncology at Tufts Medical Center and as Director of the Tufts Cancer Center in Boston, MA.

Dr. Evens is an associate editor for the British Journal of Haematology and serves on the editorial board for the Journal of Clinical Oncology. He is a core member of the Hodgkin Lymphoma Working Group for the NIH/NCI Steering Committee and has been a member of several clinical and scientific committees for the NIH, NCI, Cancer Therapy Evaluation Program (CTEP), Food and Drug Administration (FDA) and the ECOG/ACRIN group.  Dr. Evens is also an elected member of the Scientific Advisory Board for the Lymphoma Research Foundation (LRF) and he is involved in multiple national and international educational forums and events.

I completed a prior fellowship in hematology/oncology at Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center in Chicago, Illinois, where I also remained as a faculty member altogether for 10 years. Most recently, I served as the director of the Cancer Center at Tufts Medical Center in Boston, chief of their division of hematology/oncology, and Professor of Medicine at Tufts University School of Medicine.

My clinical expertise and research interests are fully dedicated to the field of lymphoma (i.e., Hodgkin lymphoma and non-Hodgkin lymphoma). Over the past 15+ years, I have been the principal investigator of more than 80 national and international cancer clinical trials that have included phase I, II, and III studies, many which have been “investigator-initiated” trials studying new and novel targeted agents for the treatment of lymphoid malignancies. In addition to my clinical research, I also manage a translational laboratory studying the biology of lymphoma and to discover new and novel treatments for patients. Collectively, my research has been continuously funded by the National Institutes of Health (NIH) and the NCI since 2005. This has resulted in 200+ research abstracts at national and international cancer research symposiums, 150+ manuscripts in peer-reviewed publications, and 20+ book chapters all with an emphasis on the biology, prognosis, and treatment of lymphoma.

My involvement in the advancement of cancer research has also included leadership roles in academic journals, symposiums, cancer advocacy groups, and international committees. I was an associate editor for the British Journal of Haematology and on the editorial board for the Journal of Clinical Oncology and am the inaugural editor in chief for the open access journal, eJHaem. I am a core member of the Hodgkin Lymphoma Working Group for the NIH/NCI Steering Committee and I have been a member of several additional clinical and scientific committees for the NIH, NCI, Cancer Therapy Evaluation Program (CTEP), Food and Drug Administration (FDA) and the ECOG/ACRIN group. Furthermore, I am Co-Chair of the Lymphoma Committee for the ECOG-ACRIN cancer research group and am honored to be an elected member of the North American Scientific Advisory Board for the Lymphoma Research Foundation (LRF) and a member of the Board of Trustees for the Leukemia & Lymphoma Society (LLS) New Jersey Chapter. Finally, I am involved and help lead a multitude of regional, national, and international educational forums and events.

Positions:
Associate Director for Clinical Services at Rutgers Cancer Institute of New Jersey
Medical Director of the Oncology Service Line, RWJBarnabas Health
Director, Lymphoma Program, Division of Blood Disorders

Clinical Expertise:
Hodgkin lymphoma, non-Hodgkin lymphoma (all types), chronic lymphocytic leukemia, and autologous hematopoietic stem cell (or bone marrow) transplantation.

Research Interests:
Lymphoma (Hodgkin lymphoma and non-Hodgkin lymphoma)
Chronic lymphocytic leukemia and other lymphoid malignancies
Clinical trials
Translational studies, including lymphoma biology and drug discovery
Systems biology and biomarker analyses
Lymphoma epidemiology
Health Outcomes, including Pharmacovigilance and Decision Making

I am thrilled to be a member of the Rutgers Cancer Institute of New Jersey (CINJ) as the Associate Director for Clinical Services, Medical Director of the Oncology Service Line for RWJBarnabas Health, and Director of the Lymphoma Program. Rutgers Cancer Institute is unique in that it is New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center. Our mission is to deliver integrated cancer care across the health system with access to academic expertise and innovative cancer therapies not available elsewhere in the state.

Showing results 1 – 6 of 6

Chat now!
0.39784